Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis
Psoriasis Treatment Center of Central New Jersey
Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Description
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of moderate to severe atopic dermatitis as defined at baseline by: * EASI score of 16 or greater, * IGA score of 3 or greater * BSA of 10% or greater, Exclusion Criteria: * Subjects with previous exposure to dupilumab. * Known or suspected hypersensitivity to dupilumab or any of its excipients. * History of photosensitivity.
Interventions
- DrugDupixent
dupilumab 300mg
Location
- Eczema Treatment Center of New JerseyEast Windsor, New Jersey